OCGN Jan 2024 7.500 call
| Previous close | 0.6000 |
| Open | 0.6000 |
| Bid | 0.4100 |
| Ask | 0.6600 |
| Strike | 7.50 |
| Expiry date | 2024-01-19 |
| Day's range | 0.6000 - 0.6400 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.13k |
- Bloomberg
Twitter Accounts Hyped Company Seeking Covid Vaccine Trials
(Bloomberg) -- A network of Twitter accounts pushed messages to boost the share price of a biotech company as it sought approval to run a clinical trial of its Covid-19 vaccine, according to research provided to Bloomberg News. Most Read from BloombergSwitzerland Imports Russian Gold for First Time Since WarStocks Surge After $2 Trillion Wipeout; Bonds Fall: Markets WrapLiz Cheney Is Paying the Price in Her Home State for Crossing TrumpUS Futures Gain With European Stocks; Dollar Slips: Markets
- GlobeNewswire
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American commercialization rights for COVAXIN™ MALVERN, Pa., June 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced the publication of positive pediatric Phase 2/3
- GlobeNewswire
Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the “2022 Best Places to Work.” “This recognition validates our efforts to build a great corporate culture, since employees are the ones surveyed for this honor,” said Dr. Shankar Musunuri, Chairman, CEO an
